coagulopathies after vaccination against sars-cov-2: the sole solution might lead to another problem

The common reported adverse impacts of covid-19 vaccination include the injection site’s local reaction followed by various non-specific flu-like symptoms. nevertheless, uncommon cases of vaccine-induced immune thrombotic thrombocytopenia (vitt) and cerebral venous sinus thrombosis (cvst) following viral vector vaccines (chadox1 ncov-19 vaccine, ad26.cov2 vaccine) have been reported. this literature review was performed using pubmed and google scholar databases using appropriate keywords and their combinations: sars-cov-2, adenovirus, spike protein, thrombosis, thrombocytopenia, vaccine-induced immune thrombotic thrombocytopenia (vitt), nf-kappab, adenoviral vector, platelet factor 4 (pf4), covid-19 vaccine, astrazeneca covid vaccine, chadox1 ncov- 19 covid vaccine, azd1222 covid vaccine, coagulopathy. the abstracts and titles of each article were assessed by authors for screening and inclusion english reports about post-vaccine cvst and vitt in humans were also collected. some sars-cov-2 vaccines based on viral vector, mrna, or inactivated sars-cov-2 virus have been accepted and are being pragmatic global. nevertheless, the recent augmented statistics of normally very infrequent types of thrombosis associated with thrombocytopenia have been stated, predominantly in the context of the adenoviral vector vaccine chadox1 ncov-19 from astra zeneca. the numerical prevalence of these side effects seems to associate with this particular vaccine type, i.e., adenoviral vector-based vaccines, but the meticulous molecular mechanisms are still not clear. the present review summarizes the latest data and hypotheses for molecular and cellular mechanisms into one integrated hypothesis demonstrating that coagulopathies, including thromboses, thrombocytopenia, and other associated side effects, are correlated to an interaction of the two components in the covid-19 vaccine.